Cargando…
Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis
INTRODUCTION: Renin-angiotensin system (RAS) plays a key role in various types of cardiovascular disease and many kinds of RAS inhibitors have been developed. The effect of discontinuation of RAS inhibitors on clinical outcomes is still controversial. This study aims to evaluate the effects of disco...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163520/ https://www.ncbi.nlm.nih.gov/pubmed/37137558 http://dx.doi.org/10.1136/bmjopen-2022-070345 |
_version_ | 1785037899124703232 |
---|---|
author | Suzuki, Taihei Nishiwaki, Hiroki Watanabe, Yoshitaka Abe, Yoshifusa Noma, Hisashi Ota, Erika Honda, Hirokazu Hasegawa, Takeshi |
author_facet | Suzuki, Taihei Nishiwaki, Hiroki Watanabe, Yoshitaka Abe, Yoshifusa Noma, Hisashi Ota, Erika Honda, Hirokazu Hasegawa, Takeshi |
author_sort | Suzuki, Taihei |
collection | PubMed |
description | INTRODUCTION: Renin-angiotensin system (RAS) plays a key role in various types of cardiovascular disease and many kinds of RAS inhibitors have been developed. The effect of discontinuation of RAS inhibitors on clinical outcomes is still controversial. This study aims to evaluate the effects of discontinuing RAS inhibitor medication on the clinical outcomes of patients continuously taking these agents. METHODS AND ANALYSIS: This article presents a systematic review protocol described in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. We will include randomised controlled trials in which the effects of RAS inhibitor withdrawal were evaluated. Initially, four authors will search for eligible studies in MEDLINE, EMBASE, the Cochrane Database Trial Register, European trial registry and ClinicalTrials.gov. Abstracts and full-text screenings will be performed by the four authors with data extraction performed by each author independently. We will include patients taking RAS inhibitors—including ACE inhibitor, angiotensin receptor blocker and angiotensin receptor neprilysin inhibitor and exclude the patients undergoing renal replacement therapy (RRT), adolescents (under 18 years of age) and patients with acute infectious diseases. Our search will be performed on 1 May 2023. Studies in which the patients discontinued RAS inhibitors due to any reason will be included. Patients who continuously took RAS inhibitors under conditions in which the intervention group discontinued these agents will be considered eligible as the comparison group. Death (any cause), Death (cardiovascular disease (CVD)) and CVD events will be set as primary outcomes. Secondary outcomes will be set as RRT, acute kidney injury, renal function (analysis of the change in estimated glomerular filtration rate), hyperkalaemia, proteinuria and blood pressure. ETHICS AND DISSEMINATION: Research ethics approval was not required in this study due to it being a systematic review, and any data belonging to individuals cannot be identified. The results of this study will be disseminated through peer-reviewed journals and conferences. TRIAL REGISTRATION NUMBER: PROSPERO CRD42022300777. |
format | Online Article Text |
id | pubmed-10163520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-101635202023-05-07 Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis Suzuki, Taihei Nishiwaki, Hiroki Watanabe, Yoshitaka Abe, Yoshifusa Noma, Hisashi Ota, Erika Honda, Hirokazu Hasegawa, Takeshi BMJ Open Cardiovascular Medicine INTRODUCTION: Renin-angiotensin system (RAS) plays a key role in various types of cardiovascular disease and many kinds of RAS inhibitors have been developed. The effect of discontinuation of RAS inhibitors on clinical outcomes is still controversial. This study aims to evaluate the effects of discontinuing RAS inhibitor medication on the clinical outcomes of patients continuously taking these agents. METHODS AND ANALYSIS: This article presents a systematic review protocol described in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. We will include randomised controlled trials in which the effects of RAS inhibitor withdrawal were evaluated. Initially, four authors will search for eligible studies in MEDLINE, EMBASE, the Cochrane Database Trial Register, European trial registry and ClinicalTrials.gov. Abstracts and full-text screenings will be performed by the four authors with data extraction performed by each author independently. We will include patients taking RAS inhibitors—including ACE inhibitor, angiotensin receptor blocker and angiotensin receptor neprilysin inhibitor and exclude the patients undergoing renal replacement therapy (RRT), adolescents (under 18 years of age) and patients with acute infectious diseases. Our search will be performed on 1 May 2023. Studies in which the patients discontinued RAS inhibitors due to any reason will be included. Patients who continuously took RAS inhibitors under conditions in which the intervention group discontinued these agents will be considered eligible as the comparison group. Death (any cause), Death (cardiovascular disease (CVD)) and CVD events will be set as primary outcomes. Secondary outcomes will be set as RRT, acute kidney injury, renal function (analysis of the change in estimated glomerular filtration rate), hyperkalaemia, proteinuria and blood pressure. ETHICS AND DISSEMINATION: Research ethics approval was not required in this study due to it being a systematic review, and any data belonging to individuals cannot be identified. The results of this study will be disseminated through peer-reviewed journals and conferences. TRIAL REGISTRATION NUMBER: PROSPERO CRD42022300777. BMJ Publishing Group 2023-05-03 /pmc/articles/PMC10163520/ /pubmed/37137558 http://dx.doi.org/10.1136/bmjopen-2022-070345 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Cardiovascular Medicine Suzuki, Taihei Nishiwaki, Hiroki Watanabe, Yoshitaka Abe, Yoshifusa Noma, Hisashi Ota, Erika Honda, Hirokazu Hasegawa, Takeshi Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis |
title | Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis |
title_full | Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis |
title_fullStr | Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis |
title_full_unstemmed | Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis |
title_short | Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis |
title_sort | outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163520/ https://www.ncbi.nlm.nih.gov/pubmed/37137558 http://dx.doi.org/10.1136/bmjopen-2022-070345 |
work_keys_str_mv | AT suzukitaihei outcomesofdiscontinuingreninangiotensinsysteminhibitorsastudyprotocolforconductingsystematicreviewandmetaanalysis AT nishiwakihiroki outcomesofdiscontinuingreninangiotensinsysteminhibitorsastudyprotocolforconductingsystematicreviewandmetaanalysis AT watanabeyoshitaka outcomesofdiscontinuingreninangiotensinsysteminhibitorsastudyprotocolforconductingsystematicreviewandmetaanalysis AT abeyoshifusa outcomesofdiscontinuingreninangiotensinsysteminhibitorsastudyprotocolforconductingsystematicreviewandmetaanalysis AT nomahisashi outcomesofdiscontinuingreninangiotensinsysteminhibitorsastudyprotocolforconductingsystematicreviewandmetaanalysis AT otaerika outcomesofdiscontinuingreninangiotensinsysteminhibitorsastudyprotocolforconductingsystematicreviewandmetaanalysis AT hondahirokazu outcomesofdiscontinuingreninangiotensinsysteminhibitorsastudyprotocolforconductingsystematicreviewandmetaanalysis AT hasegawatakeshi outcomesofdiscontinuingreninangiotensinsysteminhibitorsastudyprotocolforconductingsystematicreviewandmetaanalysis |